Heart and kidney protection study for chronic kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic kidney disease (CKD) with a certain level of kidney function (eGFR) and, if needed, protein in your urine.
- Your kidney function (eGFR) is between 20 and 45 (or between 45 and 90 with protein in urine, depending on diabetes status).
- You are not currently taking certain blood pressure or heart failure medicines called mineralocorticoid receptor antagonists (like spironolactone, eplerenone, finerenone).
- You are not on dialysis, do not have a kidney transplant, and are not scheduled for one.
- You have not had new immunosuppressive treatment for kidney disease in the last 60 days.
- You are not taking more than one ACE inhibitor or ARB (blood pressure medicines) at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial tests if empagliflozin, a daily pill, is safe and helps children ages 2–17 with chronic kidney disease (CKD). Your child may be eligible if they have reduced kidney function and elevated protein in their urine, and are already on stable kidney treatments.
This study tests a new combination of two medicines (balcinrenone and dapagliflozin) for people with heart failure and reduced kidney function. The goal is to see if this combination helps improve heart and kidney health better than current treatments.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
Hear when a new Kidney Disease, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.